In severe hemophilia A, early prophylaxis and regular physical activity were linked to lower joint damage in a real-world ...

Columnist Jennifer Lynne continues the story of hemophilia awareness advocate Lee Hall, who faced constant health threats while young.

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene therapy for severe hemophilia A.

Treatment options have improved care, but also increased the need for patient education. The article outlined some of the key considerations for physicians and discussed emerging treatment options. In ...

Mean factor IX activity level remained stable at 36.1 ± 15.7 IU/dL at year 5, with 80% of participants maintaining levels ≥ 12 IU/dL. Adjusted annualized bleeding rates decreased from 4.16 during lead ...

SAN DIEGO — Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer product to become the second US Food and Drug Administration (FDA) ...